Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER)

https://doi.org/10.20996/1819-6446-2014-10-3-288-292

Full Text:

Abstract

Aim. To evaluate the frequency of the prescription of cardiovascular drugs in patients before the reference acute myocardial infarction (AMI) based on the register "LIS-1" (Lubertsy mortality study of patients after myocardial infarction).

Material and methods. Stage 1: development of the Register of patients with AMI admitted to cardiology departments of hospitals in Luberets district, Moscow region (2005-2007) and discharged for outpatient treatment. Median follow-up – 1.6 years (1.0, 2.4). The primary endpoint – total mortality. Stage 2: the continuation of register "LIS-1" (2011-2012).

Results.1133 patients (mean age of men 60.1±0.5, women – 71.4±0.4 years) were included in the 1st stage of the study; 172 (15.2%) died in the hospital. Before the reference hospitalization 21.4% of patients had been receiving b-blockers, 35.3% - renin-angiotensin-aldosterone system (RAAS) inhibitors, 15.7% - antiplatelet agents, 1.9% - statins, 13% of patients - diuretics. Statistically significant (adjusted for sex and age) positive impact on hospital mortality reduction had a treatment with b-blockers [OR=0.542, CI=0.357-0.824, p=0.004] and RAAS inhibitors [OR=0.710; CI=0.512-0.986, p=0.040] prior to the development of acute myocardial infarction. As the number of patients receiving statins and antiplatelet agents was small, the contribution these drugs intake on hospital mortality was not identified. 272 patients (mean age 63.6±12.6 years) were included on the second phase of the study. The information about the received therapy before reference hospitalization was reported by 173 patients: 39% of patients used b-blockers, 47% - RAAS inhibitors, 37% - antiplatelet agents, 15% - statins, 15% of patients - diuretics. Positive changes in the frequency of the prescription of essential drugs were observed in 5 years: a significant increase in number of patients with b-blockers (p<0.001), RAAS inhibitors (p<0.01), antiplatelet agents (p<0.05) and statins (p<0.001). The number of patients with diuretics did not significantly change.

Conclusion. The Register "LIS-1" (Lubertsy study of mortality in patients after myocardial infarction) allowed not only to assess data on clinical practice at a certain period, but also to evaluate the changes in drug therapy of patients with high and very high cardiovascular risk.

About the Authors

M. L. Ginzburg
State Research Centre for Preventive Medicine, Lyubertsy Regional Hospital №2
Russian Federation

Petroverigsky per. 10, Moscow, 101990 Russia

Oktyabr’skiy prospect 338, Moscow Region, Lyubertsy, 140006 Russia



S. Y. Martsevich
State Research Centre for Preventive Medicine, I.M. Sechenov First Moscow State Medical University
Russian Federation

Petroverigsky per. 10, Moscow, 101990 Russia

Trubetskaya ul. 8-2, Moscow, 119991 Russia



N. P. Kutishenko
State Research Centre for Preventive Medicine, I.M. Sechenov First Moscow State Medical University
Russian Federation

Petroverigsky per. 10, Moscow, 101990 Russia

Trubetskaya ul. 8-2, Moscow, 119991 Russia



Y. V. Lukina
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. D. Deev
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


References

1. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics – 2014 Update. A Report From the American Heart Association. Circulation 2014; 129: e28-e292.

2. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. The Essentials (3rd ed). Baltimore: Lippincott Williams & Wilkins; 1996.

3. Stanley K. Evaluation of randomized controlled trials. Circulation 2007;115(13):1819-22.

4. Efficacy and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. RSC Recommendations, 2011. Ration Pharmacother Cardiol 2011; 7 (5) suppl: 2-72. Russian (Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рекомендации ВНОК, 2011. Рациональная Фармакотерапия в Кардиологии 2011;7(5) приложение: 2-72).

5. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-43.

6. Kotseva K. on behalf of the EUROASPIRE Study Group. Lessons from EUROASPIRE I, II, and III surveys. Heart Metab 2011;50:32-5.

7. Ehrlich AD, Kharchenko MS, Barbarash OL, et al. Degree of commitment to the implementation of guidelines for the treatment of acute coronary syndrome in clinical practice Russian hospitals and outcomes during hospitalization (data register "RECORD-2." Cardiology 2013; 53 (1): 14-22. Russian (Эрлих А.Д., Харченко М.С., Барбараш О.Л., и соавт. Степень приверженности к выполнению руководств по лечению острого коронарного синдрома в клинической практике российских стационаров и исходы в период госпитализации (данные регистра «РЕКОРД-2». Кардиология 2013; 53(1): 14-22).

8. Reshet'ko OV Magdeyev RM, Furman NV. Analysis of pharmacotherapy of acute coronary syndrome in the prehospital treatment. Ration Pharmacother Cardiol 2007; (5): 4-8. Russian (Решетько О.В., Магдеев Р.М., Фурман Н.В. Анализ фармакотерапии острого коронарного синдрома на догоспитальном этапе лечения. Рациональная Фармакотерапия в Кардиологии 2007; (5): 4-8).

9. Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User’s Guide, 2010. Available at: http://www.effectivehealthcare.ahrq.gov/repFiles/PatOutcomes.pdf. Accessed by 15.04.2014.

10. Boitsov SA, Martsevich SYu, Kutishenko NP, et al. Registers in cardiology. Basic rules of conduct and a real opportunity. Cardiovascular Therapy and Prevention 2013; 12 (1): 4-9. Russian (Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., и др. Регистры в кардиологии. Основные правила проведения и реальные возможности. Кардиоваскулярная Терапия и Профилактика 2013; 12 (1): 4-9).

11. Lukina Yu.V., Ginzburg M.L., Smirnov V.P. et al. Adherence to treatment preceding hospitalization in patients with acute coronary syndrome. Clinicist 2012; (2): 45-53. Russian (Лукина Ю.В., Гинзбург М.Л., Смирнов В.П. и др. Приверженность к лечению, предшествующему госпитализации, у пациентов с острым коронарным синдромом. Клиницист 2012; (2): 45-53.

12. Ginsburg ML, Kutishenko NP, Deev AD et al. The LIS study (Lubertsy mortality study of patients with acute myocardial infarction). Evaluation of drug therapy. Part 2. Influence of prior drug therapy on long-term prognosis of life of patients. Ration Pharmacother Cardiol 2012; 8 (6): 738-45. Russian (Гинзбург М.Л., Кутишенко Н.П., Деев А.Д. и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда). Оценка лекарственной терапии. Часть 2. Влияние предшествующей лекарственной терапии на отдаленный прогноз жизни больных. Рациональная Фармакотерапия в Кардиологии 2012;8(6):738-45).

13. Martsevich SY, Ginsburg ML, Kutishenko NP et al. The LIS study (Lubertsy mortality study of patients with acute myocardial infarction): Portrait of the patient. Cardiovascular Therapy and Prevention 2011; 10 (6) :89-93. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда): портрет заболевшего. Кардиоваскулярная Терапия и Профилактика 2011;10(6):89-93).

14. Oshchepkova EV. Mortality from cardiovascular diseases in the Russian Federation and the ways to reduce it. Cardiology 2009; (2): 267-72. Russian (Ощепкова Е.В. Смертность населения от сердечно-сосудистых заболеваний в Российской Федерации и пути по ее снижению. Кардиология 2009;(2):267-72).

15. Martsevich SY, Ginsburg ML, Kutishenko NP, et al. The LIS Study (Lubertsy mortality study of patients with acute myocardial infarction). Evaluation of drug therapy. Part 1. As patients are treated prior myocardial infarction, and how this affects mortality in the hospital. Ration Pharmacother Cardiol 2012; 8 (5): 681-4. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П., и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда). Оценка лекарственной терапии. Часть 1. Как лечатся больные перед инфарктом миокарда, и как это влияет на смертность в стационаре. Рациональная Фармакотерапия в Кардиологии 2012;8(5):681-4).

16. Flint A.C., Kame lH., Navi B.B. etal. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 2012;78(21):1678-83.

17. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014: 11; 276-89.


For citation:


Ginzburg M.L., Martsevich S.Y., Kutishenko N.P., Lukina Y.V., Deev A.D. THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER). Rational Pharmacotherapy in Cardiology. 2014;10(3):288-292. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-3-288-292

Views: 342


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)